Prelude Capital Management’s Revance Therapeutics, Inc. RVNC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-202,180
| Closed | -$615K | – | 1483 |
|
|
2024
Q4 | $615K | Sell |
202,180
-1,020
| -0.5% | -$3.1K | 0.04% | 430 |
|
|
2024
Q3 | $1.05M | Buy |
+203,200
| New | +$1.05M | 0.06% | 323 |
|
|
2019
Q3 | – | Sell |
-1,880
| Closed | -$24K | – | 1671 |
|
|
2019
Q2 | $24K | Buy |
+1,880
| New | +$24K | ﹤0.01% | 905 |
|
|
2018
Q4 | – | Sell |
-200
| Closed | -$5K | – | 1809 |
|
|
2018
Q3 | $5K | Buy |
+200
| New | +$5K | ﹤0.01% | 1268 |
|
|
2018
Q2 | – | Sell |
-12,970
| Closed | -$399K | – | 1719 |
|
|
2018
Q1 | $399K | Sell |
12,970
-4,012
| -24% | -$123K | 0.03% | 436 |
|
|
2017
Q4 | $607K | Buy |
16,982
+6,749
| +66% | +$241K | 0.05% | 320 |
|
|
2017
Q3 | $282K | Sell |
10,233
-5,892
| -37% | -$162K | 0.03% | 482 |
|
|
2017
Q2 | $426K | Buy |
16,125
+12,549
| +351% | +$332K | 0.04% | 318 |
|
|
2017
Q1 | $74K | Buy |
+3,576
| New | +$74K | 0.01% | 828 |
|
|
2016
Q1 | – | Sell |
-1,300
| Closed | -$44K | – | 1492 |
|
|
2015
Q4 | $44K | Buy |
+1,300
| New | +$44K | 0.01% | 1004 |
|